Trials / Completed
CompletedNCT00002202
A Comparison of 141W94 and Indinavir in HIV-Infected Patients
A Phase III Trial to Compare the Safety and Antiviral Efficacy of 141W94 With Indinavir in Combination With Nucleoside Reverse Transcriptase Inhibitor (NRTI) Therapy, in NRTI-Experienced, Protease Inhibitor (PI)-Naive, HIV-1-Infected Patients.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 460 (planned)
- Sponsor
- Glaxo Wellcome · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to see if 141W94 is as safe and effective as indinavir when used with nucleoside reverse transcriptase inhibitors (NRTIs) for 48 weeks. This study also examines what effect other drugs have on how the body handles 141W94.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Indinavir sulfate | |
| DRUG | Amprenavir |
Timeline
- First posted
- 2001-08-31
- Last updated
- 2005-06-24
Locations
24 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00002202. Inclusion in this directory is not an endorsement.